RxDoctor Payments Data

Brad Snodgrass, MD

Internal Medicine · Lubbock, TXNPI 1134168842

Payments from drug & device makers

$295in general payments, 2019–2025

Across 16 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$63
  • Amgen$50
  • GSK$50
  • Corcept Therapeutics$29
  • Sumitomo Pharma America, Inc.$23
  • Eisai Inc.$22
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$295 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$214,619
Medicare patients
391
Services billed
10,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$179,459
FarxigaDapagliflozin Propanediol93$112,876
TrulicityDulaglutide105$107,506
XareltoRivaroxaban34$44,260
MounjaroTirzepatide33$34,128
OzempicSemaglutide38$33,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$23,581
JanuviaSitagliptin Phosphate17$22,740
EntrestoSacubitril/Valsartan14$18,436
JardianceEmpagliflozin18$17,267
LinzessLinaclotide17$12,848
Repatha SureclickEvolocumab23$12,440
PremarinEstrogens, Conjugated21$7,385
MyrbetriqMirabegron13$7,112
InvokanaCanagliflozin12$7,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$33,59138 claims
GSKTrelegy Ellipta, Anoro Ellipta$50$30,18847 claims
MerckJanuvia$14$22,74017 claims
AbbVieLinzess, Synthroid$63$16,13787 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →